Dr Reddy's Laboratories (DRL) is optimistic about a recovery in FY27 following a 26% decline in net profit during FY26, primarily due to challenges in the US market. The March quarter saw an 86% drop in profit, influenced by one-time charges. Despite these setbacks, DRL's operations in India, Europe, and emerging markets have shown healthy growth. The company anticipates improved margins in FY27, driven by a better product mix, effective cost controls, and no significant one-off expenses. A key factor in this growth is the launch of Semaglutide in India and its recent approval in Canada. Additionally, while US revenues were under strain due to the loss of exclusivity for Revlimid, DRL expects its base generics business to achieve double-digit growth, aided by 27 new product launches. The company is also investing ₹2,000 crore (approximately $240 million USD) in capital expenditures, focusing on biosimilars and product-specific advancements. Furthermore, R&D costs have decreased by 25% year-on-year, allowing for a strategic shift towards partnership-led biologics development.